** Shares of drugmaker Ultragenyx Pharmaceutical RARE.O rise 2% to $38.75
** JPMorgan raises RARE's target price to $117 from $104
** Believes RARE is uniquely positioned in the long term with a broad and diverse pipeline of orphan disease assets and a highly regarded management team - JPMorgan
** 19 of 20 brokerages rate the stock "buy" or higher, one "hold"; their median PT is $87, according to data compiled by LSEG
** Up to last close, stock had fallen ~10% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.